Through consultation with the tumor testing laboratory, it was determined the protein alterations reported through tumor profiling were predicted based on the following DNA findings: c.1929delG in BRCA2 and c.2080G>T in MLH1. Testing was performed using targeted PCR-based amplification of the relevant coding exon followed by dideoxy termination (Sanger) sequencing. The gene discussed is MLH1; the disease is neoplasm.